The role of iron in cell cycle progression and the proliferation of neoplastic cells

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1603, Issue 1, 2002, Pages 31-46

  Le, Nghia T V ^a   Richardson, Des R ^a  

^a HEART RESEARCH INSTITUTE   (Australia)

Author keywords

Cancer; Iron; Iron chelation; Iron chelator; Iron metabolism; p21; p53; Ribonucleotide reductase

Indexed keywords

2 HYDROXY 1 NAPHTHYLALDEHYDE ISONICOTINOYLHYDRAZONE; 3 AMINOPICOLINALDEHYDE THIOSEMICARBAZONE; ANTINEOPLASTIC AGENT; APOPTOSIS INDUCING FACTOR; CHELATING AGENT; CYCLIN A; CYCLIN B; CYCLIN D; CYCLIN DEPENDENT KINASE INHIBITOR; DEOXYRIBONUCLEOTIDE; DOXORUBICIN; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; HYDROXYUREA; HYPOXIA INDUCIBLE FACTOR 1; IRON; MESSENGER RNA; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PROTEIN BAX; PROTEIN DERIVATIVE; PROTEIN MDM2; PROTEIN NOXA; PROTEIN P21; PROTEIN P53; RETINOBLASTOMA PROTEIN; RIBONUCLEOTIDE; RIBONUCLEOTIDE REDUCTASE; SERINE; TACHPYRIDINE; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BINDING SITE; CANCER INHIBITION; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CLINICAL TRIAL; DNA REPAIR; DNA SYNTHESIS; DRUG EFFICACY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME SUBUNIT; GROWTH REGULATION; HUMAN; IRON CHELATION; IRON DEPLETION; IRON METABOLISM; IRON TRANSPORT; MOLECULAR MECHANICS; NEOVASCULARIZATION (PATHOLOGY); NEUROBLASTOMA; NONHUMAN; ONCOGENE C MYB; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; REGULATORY MECHANISM; REVIEW; TUMOR CELL;

AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL CYCLE PROTEINS; CLINICAL TRIALS, PHASE II; DNA DAMAGE; DNA-BINDING PROTEINS; DRUG DELIVERY SYSTEMS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MYC; HUMANS; IRON; IRON CHELATING AGENTS; MOLECULAR SEQUENCE DATA; PYRIDINES; RIBONUCLEOTIDE REDUCTASES; RNA-BINDING PROTEINS; THIOSEMICARBAZONES; TRANSCRIPTION FACTORS;

MURINAE;

EID: 0037009846     PISSN: 0304419X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-419X(02)00068-9     Document Type: Review

References (167)

1. Hershko C. Control of disease by selective iron depletion: a novel therapeutic strategy utilizing iron chelators. Bailliere's Clin. Haematol. 7:1994;965-1000.
2. Richardson D.R. Potential of iron chelators as effective anti-proliferative agents. Can. J. Physiol. Pharm. 75:1997;1164-1180.
3. Richardson D.R. Analogues of pyridoxal isonicotinoyl hydrazone (PIH) as potential Fe chelators for the treatment of neoplasia. Leuk. Lymphoma. 31:1998;47-60.
4. Ivan M., Kondo K., Yang H., Kim W., Valiando J., Ohh M., Salic A., Asara J.M., Lane W.S., Kaelin W.G. Jr. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science. 292:2001;464-468.
5. Jaakkola P., Mole D.R., Tian Y.M., Wilson M.I., Gielbert J., Gaskell S.J., Kriegsheim A., Hebestreit H.F., Mukherji M., Schofield C.J., Maxwell P.H., Pugh C.W., Ratcliffe P.J. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 292:2001;468-472.
6. Oppenheim E.W., Nasrallah T.M., Mastri M.G., Stover P.J. Mimosine is a cell-specific antagonist of folate metabolism. J. Biol. Chem. 275:2000;19268-19274.
7. Lederman H.M., Cohen A., Lee J.W., Freedman M.H., Gelfand E.W. Deferoxamine: a reversible S-phase inhibitor of human lymphocyte proliferation. Blood. 64:1984;748-753.
8. Morgan E.H. Transferrin: biochemistry, physiology and clinical significance. Mol. Aspects Med. 4:1981;1-123.
9. Andrews N.C. Disorders of iron metabolism. N. Engl. J. Med. 341:1999;1986-1995.
10. Richardson D.R., Ponka P. The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells. Biochim. Biophys. Acta. 1331:1997;1-40.
11. Ponka P., Beaumont C., Richardson D.R. Function and regulation of transferrin and ferritin. Semin. Hematol. 35:1998;35-54.
12. Kawabata H., Yang R., Hirama T., Vuong P.T., Kawano S., Gombart A.F., Koeffler H.P. Molecular cloning of transferrin receptor 2: a new member of the transferrin receptor-like family. J. Biol. Chem. 274:1999;20826-20832.
13. Kawabata H., Germain R.S., Vuong P.T., Nakamaki T., Said J.W., Koeffler H.P. Transferrin receptor 2-α supports cell growth both in iron-chelated cultured cells and in vivo. J. Biol. Chem. 275:2000;16618-16625.
14. Fleming M.D., Trenor C.C., Su M.A., Foernzler D., Beier D.R., Dietrich W.F., Andrews N.C. Microcytic anaemia mice have a mutation in Nramp2, a candidate iron transporter gene. Nat. Genet. 16:1997;383-386.
15. Gunshin H., MacKenzie B., Berger U.V., Gunshin Y., Romero M.F., Boron W.F., Nussberger S., Gollan J.L., Hediger M.A. Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature. 388:1997;482-488.
16. Harrison P.M., Arosio P. The ferritins: molecular properties, iron storage function and cellular regulation. Biochim. Biophys. Acta. 1275:1996;161-203.
17. Ponka P. Tissue specific regulation of iron metabolism and heme synthesis: distinct control mechanisms in erythoid cells. Blood. 89:1997;1-25.
18. Jacobs A. Low molecular weight intracellular iron transport compounds. Blood. 50:1977;433-439.
19. Harrison M.D., Jones C.E., Dameron C.T. Copper chaperones: function, structure and copper-binding properties. J. Biol. Inorg. Chem. 4:1999;145-153.
20. Hentze M.W., Kuhn C. Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide and oxidative stress. Proc. Natl. Acad. Sci. U. S. A. 93:1996;8175-8182.
21. Larrick J.W., Cresswell P. Modulation of cell surface iron transferrin receptors by cellular density and state of activation. J. Supramol. Struct. 11:1979;579-586.
22. Richardson D.R., Baker E. The uptake of iron and transferrin by the human malignant melanoma cell. Biochim. Biophys. Acta. 1053:1990;1-12.
23. Richardson D.R., Baker E. The effect of desferrioxamine and ferric ammonium citrate on the uptake of iron by the membrane iron-binding component of human melanoma cells. Biochim. Biophys. Acta. 1103:1992;275-280.
24. Trinder D., Zak O., Aisen P. Transferrin receptor-independent uptake of differic transferrin by human hepatoma cells with antisense inhibition of receptor expression. Hepatology. 23:1996;1512-1520.
25. Chitamber C.R., Seligman P.A. Effects of different transferrin forms on transferrin receptor expression, iron uptake, and cellular proliferation of human leukemic HL60 cells: mechanisms responsible for the specific cytotoxicity of transferrin-gallium. J. Clin. Invest. 78:1986;1538-1546.
26. Chan S.M., Hoffer P.B., Maric N., Duray P. Inhibition of gallium-67 uptake in melanoma by an anti-human transferrin receptor monoclonal antibody. J. Nucl. Med. 28:1987;1303-1307.
27. Hileti D., Panayiotidis P., Hoffbrand A.V. Iron chelators induce apoptosis in proliferating cells. Br. J. Haematol. 89:1995;181-187.
28. Lovejoy D., Richardson D.R. Novel "hybrid" iron chelators derived from aroylhydrazones and thiosemicarbazones demonstrate high anti-proliferative activity that is selective for tumor cells. Blood. 100:2002;666-676.
29. Trowbridge I.S., Lopez F. Monoclonal antibody to transferrin receptor blocks transferrin binding and inhibits tumor cell growth in vitro. Proc. Natl. Acad. Sci. U. S. A. 79:1982;1175-1179.
30. Kemp J.D., Thorson J.A., Stewart B.C., Nauman P.W. Inhibition of hematopoietic tumour growth by combined treatment with deferoxamine and an IgG monoclonal antibody against the transferrin receptor: evidence for a theshold model of iron deprivation toxicity. Cancer Res. 52:1992;4144-4148.
31. Kemp J.D., Cardillo T., Stewart B.C., Kehrberg E., Weiner G., Hedlund B., Naumann P.W. Inhibition of lymphoma growth in vivo by combined treatment with hydroxyethyl starch deferoxamine conjugate and IgG monoclonal antibodies against the transferrin receptor. Cancer Res. 55:1995;3817-3824.
32. Kemp J.D. Iron deprivation and cancer: a view beginning with studies of monoclonal antibodies against the transferrin receptor. Histol. Histopathol. 12:1997;291-296.
33. Hibbs J.B. Jr., Taintor R.R., Vavrin Z. Iron deprivation: possible cause of tumour cell cytoxicity induced by activated macrophages. Biochem. Biophys. Res. Commun. 123:1984;716-723.
34. Hibbs J.B. Jr., Taintor R.R., Vavrin Z., Rachlin E.M. Nitric oxide: a cytotoxic activated macrophage effector molecule. Biochem. Biophys. Res. Commun. 157:1988;87-94.
35. Watts R.N., Richardson D.R. Nitrogen monoxide (NO) and glucose: unexpected links that affect intracellular iron metabolism and iron mobilisation. J. Biol. Chem. 276:2001;4724-4732.
36. Wardrop S.L., Watts R., Richardson D.R. Nitrogen monoxide (NO) activates IRP-RNA binding by two possible mechanisms - an effect on the Fe-S cluster and iron release from cells. Biochemistry. 39:2000;2748-2758.
37. Nestle F.P., Greene R.N., Kichian K., Ponka P., Lapp W.S. Activation of macrophage cytostatic effector mechanisms during acute graft-versus-host disease: release of intracellular iron and nitric oxide-mediated cytostasis. Blood. 96:2000;1836-1843.
38. Feger F., Ferry-Dumazet H., Mamani Matsuda M., Bordenave J., Dupouy M., Nussler A.K., Arock M., Devevey L., Nafziger J., Guillosson J.J., Reiffers J., Mossalayi M.D. Role of iron in tumor cell protection from the pro-apoptotic effect of nitric oxide. Cancer Res. 61:2001;5289-5294.
39. Richardson D.R., Neumannova V., Ponka P. Nitrogen monoxide decreases iron uptake from transferrin but does not mobilise iron from prelabelled neoplastic cells. Biochim. Biophys. Acta. 1266:1995;250-260.
40. Watts R.N., Richardson D.R. Examination of the mechanism of action of nitrogen monoxide on iron uptake from transferrin. J. Lab. Clin. Med. 136:2000;149-156.
41. Thelander L., Reichard P. Reduction of ribonucleotides. Annu. Rev. Biochem. 48:1979;133-158.
42. Thelander L., Gräslund A., Thelander M. Continual presence of oxygen and iron are required for mammalian ribonucleotide reduction: possible regulation mechanism. Biochem. Biophys. Res. Commun. 110:1983;859-865.
43. Salmon S.E. Part VII. Chemotherapeutic agents: cancer chemotherapy. Meyers F.H., Jawetz E., Goldfien E. Review of Medical Pharmacology. 7th edn. 1980;Lange Medical Publications, California. Chapter 45.
44. Nyholm S., Thelander L., Gräslund A. Reduction and loss of the iron centre in the reaction of the small subunit of mouse ribonucleotide reductase with hydroxyurea. Biochemistry. 32:1993;11569-11574.
45. Beckloff G.L., Lerner H.J., Frost D., Russo-Alesi F.M., Gitomer S. Hydroxyurea (NSC-32065) in biological fluids: dose-concentration relationship. Cancer Chemother. Rep. 48:1965;57-58.
46. Moore E.C., Hurlbert R.B. The inhibition of ribonucleoside diphosphate reductase by hydroxyurea, guanazole and pyrazoloimidazole (IMPY). Cory J.G., Cory A.H. Inhibitors of Ribonucleoside Diphosphate Reductase Activity. 1989;165-201 Pergamon, Oxford.
47. Gwilt P.R., Tracewell W.G. Pharmacokinetics and pharmacodynamics of hydroxyurea. Clin. Pharmacokinet. 34:1998;347-358.
48. Takeda E., Weber G. Role of ribonucleotide reductase in expression in the neoplastic program. Life Sci. 28:1981;1007-1014.
49. Witt L., Yap T., Blakley R.L. Regulation of ribonucleotide reductase activity and its possible exploitation in chemotherapy. Adv. Enzyme Regul. 17:1978;157-171.
50. Salmon S. Chemotherapeutic agents - cancer chemotherapy. Meyers F., Jawetz E., Goldfien E., Goldfien A. Review of Medical Pharmacology. 1980;77-513 Lange Medical Publications, Los Altos.
51. Finch R.A., Liu M.C., Cory A.H., Cory J.G., Sartorelli A.C. Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone; 3-AP): an inhibitor of ribonucleotide reductase with antineoplastic activity. Adv. Enzyme Regul. 39:1999;3-12.
52. Finch R.A., Liu M., Grill S.P., Rose W.C., Loomis R., Vasquez K.M., Cheng Y., Sartorelli A.C. Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone): a potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity. Biochem. Pharmacol. 59:2000;983-991.
53. Green D.A., Antholine W.E., Wong S.J., Richardson D.R., Chitambar C.R. Ribonucleotide reductase as a preferential target for the inhibition of leukemic cell growth by 311, a novel iron chelator of the pyridoxal isonicotinoyl hydrazone class. Clin. Cancer Res. 7:2001;3574-3579.
54. Chabes A., Thelander L. Controlled protein degradation regulates ribonucleotide reductase activity in proliferating mammalian cells during the normal cell cycle and in response to DNA damage and replication blocks. J. Biol. Chem. 275:2000;17747-17753.
55. Nakano K., Balint E., Ashcroft M., Vousden K.H. A ribonucleotide reductase gene is a transcriptional target of p53 and p73. Oncogene. 19:2000;4283-4289.
56. Tanaka H., Arakawa H., Yamaguchi T., Shiraishi K., Fukuda S., Matsui K., Takei Y., Nakamura Y. A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature. 404:2000;42-49.
57. Guittet O., Hakansson P., Voevodskaya N., Graslund A., Arakawa H., Nakamura Y., Thelander L. Mammalian p53R2 protein forms an active ribonucleotide reductase in vitro with the R1 protein, which is expressed both in resting cells in response to DNA damage and in proliferating cells. J. Biol. Chem. 276:2001;40647-40651.
58. Kauppi B., Nielsen B.B., Ramaswamy S., Larson I.K., Thelander M., Thelander L., Eklund H. The three-dimensional structure of mammalian ribonucleotide reductase protein R2 reveals a more-accessible iron-radical site than Escherichia coli R2. J. Mol. Biol. 262:1996;706-720.
59. Blatt J., Huntley D. Enhancement of in vitro activity against neuroblastoma by doxorubicin and deferoxamine. J. Natl. Cancer Inst. 81:1989;866-870.
60. Thompson H.J., Kennedy K., Witt M., Juzefyk J. Effect of dietary iron deficiency or excess on the induction of mammary carcinogenesis by 1-methyl-1-nitrosourea. Carcinogenesis. 12:1991;111-114.
61. Wang F., Elliott R.L., Head J.F. Inhibitory effect of deferoxamine mesylate and low iron diet on the 13762NF rat mammary adenocarcinoma. Anticancer Res. 19:1999;445-450.
62. Pickart L., Goodwin W.H., Burgua W., Murphy T.B., Johnson D.K. Inhibition of the growth of cultured cells and an implanted fibrosarcoma by aroylhydrazone analogs of the Gly-His-Lys-Cu(II) complex. Biochem. Pharmacol. 32:1983;3868-3871.
63. Hann H.W., Stahlhut M.W., Rubin R., Maddrey W.C. Antitumor effect of deferoxamine on human hepatocellular carcinoma growing in athymic nude mice. Cancer. 70:1992;2051-2056.
64. Estrov Z., Tawa A., Wang X.H., Dube I.D., Sulh H., Cohen A., Gelfand E.W., Freedman M.H. In vivo and in vitro effects of desferrioxamine in neonatal acute leukaemia. Blood. 69:1987;757-761.
65. Dezza L., Cazzola M., Danova M., Carlo-Stella C., Bergamaschi G., Brugnatelli S., Invernizzi R., Mazzini G., Riccardi A., Ascari E. Effects of desferrioxamine on normal and leukemic human hematopoietic cell growth: in vitro and in vivo studies. Leukemia. 3:1989;104-107.
66. Donfrancesco A., Deb G., Dominici C., Pileggi D., Castello M.A., Helson L. Effects of a single course of deferoxamine in neuroblastoma patients. Cancer Res. 50:1990;4929-4930.
67. Donfrancesco A., Deb G., Dominici C., Angioni A., Caniglia M., De Sio L., Fidani P., Amici A., Helson L. Deferoxamine, cyclophosphamide, etoposide, carboplatin, and thiotepa (D-CECat): a new cytoreductive chelation-chemotherapy regimen in patients with advanced neuroblastoma. Am. J. Clin. Oncol. 15:1992;319-322.
68. Donfrancesco A., De Bernardi B., Carli M., Mancini A., Nigro M., De Sio L., Casale F., Bagnulo S., Helson L., Deb G. Deferoxamine (D) followed by cytoxan (C), etoposide (E), carboplatin (Ca), thio-TEPA (T), induction regimen in advanced neuroblastoma. Eur. J. Cancer. 31A:1995;612-615.
69. Donfrancesco A., Deb G., De Sio L., Cozza R., Castellano A. Role of desferrioxamine in tumor therapy. Acta Haematol. 95:1996;66-69.
70. Richardson D.R. Iron chelators as therapeutic agents for the treatment of cancer. Crit. Rev. Oncol./Hematol. 42:2002;267-281.
71. Richardson D.R., Tran E.H., Ponka P. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as antiproliferative agents. Blood. 86:1995;4295-4306.
72. Richardson D.R., Milnes K. The potential of iron chelators of the pyridoxal isonicotinyl hydrazone class as effective antiproliferative agents II: the mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone. Blood. 89:1997;3025-3038.
73. Darnell G., Richardson D.R. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents: III. The effect of the ligands on molecular targets involved in proliferation. Blood. 94:1999;781-792.
74. Gao J., Richardson D.R. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents: IV. The mechanisms involved in inhibiting cell-cycle progression. Blood. 98:2001;842-850.
75. Torti S.V., Torti F.M., Whitman S.P., Brechbiel M.W., Park G., Planalp R.P. Tumor cell cytotoxicity of a novel metal chelator. Blood. 92:1998;1384-1389.
76. Abeysinghe R.D., Greene B.T., Haynes R., Willingham M.C., Turner J., Planalp R.P., Brechbiel M.W., Torti F.M., Torti S.V. p53-independent apoptosis mediated by tachpyridine, an anti-cancer iron chelator. Carcinogenesis. 22:2001;1607-1614.
77. Kulp K.S., Green S.L., Vulliet P.R. Iron deprivation inhibits cyclin-dependent kinase activity and decreases cyclin D/CDK4 protein levels in asynchronous MDA-MB-453 human breast cancer cells. Exp. Cell Res. 229:1996;60-68.
78. Simonart T., Degraef C., Andrei G., Mosselmans R., Hermans P., Van Vooren J.P., Noel J.C., Boelaert J.R., Snoeck R., Heenen M. Iron chelators inhibit the growth and induce the apoptosis of Kaposi's sarcoma cells and of their putative endothelial precursors. J. Invest. Dermatol. 115:2000;893-900.
79. Fukuchi K., Tomoyasu S., Watanabe H., Kaetsu S., Tsuruoka N., Gomi K. Iron deprivation results in an increase in p53 expression. Biol. Chem. Hoppe-Seyler. 376:1995;627-630.
80. Fukuchi K., Tomoyasu S., Watanabe H., Tsuruoka N., Gomi K. G1 accumulation caused by iron deprivation with deferoxamine does not accompany change of pRB status in ML-1 cells. Biochim. Biophys. Acta. 1357:1997;297-305.
81. Fukuchi K., Tomoyasu S., Nakamaki T., Tsuruoka N., Gomi K. DNA damage induces p21 protein expression by inhibiting ubiquitination in ML-1 cells. Biochim. Biophys. Acta. 1404:1998;405-411.
82. An W.G., Kanekal M., Simon M.C., Maltepe E., Blagosklonny M.V., Neckers L.M. Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha. Nature. 392:1998;405-408.
83. Sherr C.J. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res. 60:2000;3689-3695.
84. Vidal A., Koff A. Cell-cycle inhibitors: three families united by a common cause. Gene. 247:2000;1-15.
85. Maki C.G., Howley P.M. Ubiquitination of p53 and p21 is differentially affected by ionizing and UV radiation. Mol. Cell. Biol. 17:1997;355-363.
86. el-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., Lin D., Mercer W.E., Kinzler K.W., Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell. 75:1993;817-825.
87. Pagano M., Tam S.W., Theodoras A.M., Beer-Romero P., Del Sal G., Chau V., Yew P.R., Draetta G.F., Rolfe M. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science. 269:1995;682-685.
88. Tsvetkov L.M., Yeh K.H., Lee S.J., Sun H., Zhang H. p27(Kip1) ubiquitination and degradation is regulated by the SCF(Skp2) complex through phosphorylated Thr187 in p27. Curr. Biol. 9:1999;661-664.
89. Blain S.W., Montalvo E., Massague J. Differential interaction of the cyclin-dependent kinase (Cdk) inhibitor p27Kip1 with cyclin A-Cdk2 and cyclin D2-Cdk4. J. Biol. Chem. 272:1997;25863-25872.
90. Cheng M., Olivier P., Diehl J.A., Fero M., Roussel M.F., Roberts J.M., Sherr C.J. The p21(Cip1) and p27(Kip1) CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J. 18:1999;1571-1583.
91. LaBaer J., Garrett M.D., Stevenson L.F., Slingerland J.M., Sandhu C., Chou H.S., Fattaey A., Harlow E. New functional activities for the p21 family of CDK inhibitors. Genes Dev. 11:1997;847-862.
92. Alt J.R., Gladde A.B., Diehl J.A. p21Cip1 promotes cyclin D1 nuclear accumulation via direct inhibition of nuclear export. J. Biol. Chem. 277:2001;8517-8523.
93. Ruas M., Peters G. The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim. Biophys. Acta. 1378:1998;F115-F177.
94. Hollstein M., Sidransky D., Vogelstein B., Harris C.C. p53 mutations in human cancers. Science. 253:1991;49-53.
95. Levine A.J., Momand J., Finlay C.A. The p53 tumour suppressor gene. Nature. 351:1991;453-456.
96. Hainaut P., Hollstein M. p53 and human cancer: the first ten thousand mutations. Adv. Cancer Res. 77:2000;81-137.
97. Jimenez G.S., Nister M., Stommel J.M., Beeche M., Barcarse E.A., Zhang X.Q., O'Gorman S., Wahl G.M. A transactivation-deficient mouse model provides insights into Trp53 regulation and function. Nat. Genet. 26:2000;37-43.
98. Vogelstein B., Lane D., Levine A.J. Surfing the p53 network. Nature. 408:2000;307-310.
99. Linke S.P., Clarkin K.C., Di Leonardo A., Tsou A., Wahl G.M. A reversible, p53-dependent G0/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage. Genes Dev. 10:1996;934-947.
100. Vousden K.H., Woude G.F. The ins and outs of p53. Nat. Cell Biol. 2:2000;E178-E180.
101. Honda R., Tanaka H., Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420:1997;25-27.
102. Momand J., Zambetti G.P., Olson D.C., George D., Levine A.J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 69:1992;1237-1245.
103. Haupt Y., Maya R., Kazaz A., Oren M. Mdm2 promotes the rapid degradation of p53. Nature. 387:1997;296-299.
104. Carr A.M. Cell cycle. Piecing together the p53 puzzle. Science. 287:2000;1765-1766.
105. Tibbetts R.S., Brumbaugh K.M., Williams J.M., Sarkaria J.N., Cliby W.A., Shieh S.Y., Taya Y., Prives C., Abraham R.T. A role for ATR in the DNA damage-induced phosphorylation of p53. Genes Dev. 13:1999;152-157.
106. Elliott M.J., Dong Y.B., Yang H., McMasters K.M. E2F-1 up-regulates c-Myc and p14(ARF) and induces apoptosis in colon cancer cells. Clin. Cancer Res. 7:2001;3590-3597.
107. Lin A.W., Lowe S.W. Oncogenic ras activates the ARF-p53 pathway to suppress epithelial cell transformation. Proc. Natl. Acad. Sci. U. S. A. 98:2001;5025-5030.
108. Sherr C.J., Weber J.D. The ARF/p53 pathway. Curr. Opin. Genet. Dev. 10:2000;94-99.
109. Khosravi R., Maya R., Gottlieb T., Oren M., Shiloh Y., Shkedy D. Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation in response to DNA damage. Proc. Natl. Acad. Sci. U. S. A. 96:1999;14973-14977.
110. Chin L., Pomerantz J., DePinho R.A. The INK4a/ARF tumour suppressor: one gene-two products-two pathways. Trends Biochem. Sci. 23:1998;291-296.
111. Quelle D.E., Zindy F., Ashmun R.A., Sherr C.J. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell. 83:1995;993-1000.
112. Eymin B., Karayan L., Seite P., Brambilla C., Brambilla E., Larsen C.J., Gazzeri S. Human ARF binds E2F1 and inhibits its transcriptional activity. Oncogene. 10:2001;1033-1041.
113. Alcantara O., Kalidas M., Baltathakis I., Boldt D.H. Expression of multiple genes regulating cell cycle and apoptosis in differentiating hematopoietic cells is dependent on iron. Exp. Hematol. 29:2001;1060-1069.
114. Terada N., Lucas J.J., Gelfand E.W. Differential regulation of the tumor suppressor molecules, retinoblastoma susceptibility gene product (Rb) and p53, during cell cycle progression of normal human T cells. J. Immunol. 147:1991;698-704.
115. Sherr C.J. G1 phase progression: cycling on cue. Cell. 79:1994;551-555.
116. 1 phase of the cell cycle. Cancer Res. 53:1993;3968-3975.
117. Renton F.J., Jeitner T.M. Cell cycle-dependent inhibition of the proliferation of human neural tumor cell lines by iron chelators. Biochem. Pharmacol. 51:1996;1553-1561.
118. Resnitzky D., Reed S.I. Different roles for cyclins D1 and E in regulation of the G1-to-S transition. Mol. Cell. Biol. 15:1995;3463-3469.
119. Zetterberg A., Larsson O., Wiman K.G. What is the restriction point? Curr. Opin. Cell Biol. 7:1995;835-842.
120. DeGregori J., Kowalik T., Nevins J.R. Cellular targets for activation by the E2F1 transcription factor include DNA synthesis- and G1/S-regulatory genes. Mol. Cell. Biol. 15:1995;4215-4224.
121. Schimke R.T., Kung A.L., Rush D.F., Sherwood S.W. Differences in mitotic control among mammalian cells. Cold Spring Harbor Symp. Quant. Biol. 56:1991;417-423.
122. Kung A.L., Sherwood S.L., Schimke R.T. Cell line-specific differences in the control of cell cycle progression in the absence of mitosis. Proc. Natl. Acad. Sci. U. S. A. 87:1990;9553-9557.
123. Ashcroft M., Taya Y., Vousden K.H. Stress signals utilize multiple pathways to stabilize p53. Mol. Cell. Biol. 20:2000;3224-3233.
124. Gazitt Y., Reddy S.V., Alcantara O., Yang J., Boldt D.H. A new molecular role for iron in regulation of cell cycling and differentiation of HL-60 human leukemia cells: iron is required for transcription of p21(WAF1/CIP1) in cells induced by phorbol myrisate acetate. J. Cell. Physiol. 187:2001;124-135.
125. Tonetti D.A., Henning-Chubb C., Yamanishi D.T., Huberman E. Protein kinase C-β is required for macrophage differentiation of human HL-60 leukemia cells. J. Biol. Chem. 269:1994;23230-23235.
126. Alcantara O., Obeid L., Hannun Y., Ponka P., Boldt D.H. Regulation of protein kinase C (PKC) expression by iron: effect of different iron compounds on PKC-β and PKC-α gene expression and role of the 5′-flanking region of the PKC-β gene in the response to ferric transferrin. Blood. 84:1994;3510-3517.
127. Donehower L.A., Bradley A. The tumor suppressor p53. Biochim. Biophys. Acta. 1155:1993;181-205.
128. Russo T., Zambrano N., Esposito F., Ammendola R., Cimino F., Fiscella M., Jackman J., O'Connor P.M., Anderson C.W., Appella E. A p53-independent pathway for activation of WAF1/CIP1 expression following oxidative stress. J. Biol. Chem. 270:1995;29386-29391.
129. Hainaut P., Milner J. A structural role for metal ions in the "wild-type" conformation of the tumor suppressor protein p53. Cancer Res. 53:1993;1739-1742.
130. Hainaut P., Butcher S., Milner J. Temperature sensitivity for conformation is an intrinsic property of wild-type p53. Br. J. Cancer. 71:1995;227-231.
131. Sun Y., Bian J., Wang Y., Jacobs C. Activation of p53 transcriptional activity by 1,10-phenanthroline, a metal chelator and redox sensitive compound. Oncogene. 14:1997;385-393.
132. Hammond E.M., Denko N.C., Dorie M.J., Abraham R.T., Giaccia A.J. Hypoxia links ATR and p53 through replication arrest. Mol. Cell. Biol. 22:2002;1834-1843.
133. Shieh S.Y., Ikeda M., Taya Y., Prives C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell. 91:1997;325-334.
134. Unger T., Juven-Gershon T., Moallem E., Berger M., Vogt Sionov R., Lozano G., Oren M., Haupt Y. Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2. EMBO J. 18:1999;1805-1814.
135. Hupp T.R., Lane D.P. Allosteric activation of latent p53 tetramers. Curr. Biol. 4:1994;865-875.
136. Carmeliet P., Dor Y., Herbert J.M., Fukumura D., Brusselmans K., Dewerchin M., Neeman M., Bono F., Abramovitch R., Maxwell P., Koch C.J., Ratcliffe P., Moons L., Jain R.K., Collen D., Keshert E. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature. 394:1998;485-490.
137. Semenza G.L. HIF-1 and human disease: one highly involved factor. Genes Dev. 14:2000;1983-1991.
138. Suzuki H., Tomida A., Tsuruo T. Dephosphorylated hypoxia-inducible factor-1alpha as a mediator of p53-dependent apoptosis during hypoxia. Oncogene. 20:2001;5779-5788.
139. Blagosklonny M.V., An W.G., Romanova L.Y., Trepel J., Fojo T., Neckers L. p53 inhibits hypoxia-inducible factor-stimulated transcription. J. Biol. Chem. 273:1998;11995-11998.
140. Beerepoot L.V., Shima D.T., Kuroki M., Yeo K.T., Voest E.E. Up-regulation of vascular endothelial growth factor production by iron chelators. Cancer Res. 56:1996;3747-3751.
141. Daghman N.A., Elder G.E., Savage G.A., Winter P.C., Maxwell A.P., Lappin T.R. Erythropoietin production: evidence for multiple oxygen sensing pathways. Ann. Hematol. 78:1999;275-278.
142. Nyholm S., Mann G.J., Johansson A.G., Bergeron R.J., Gräslund A., Thelander L. Role of ribonucleotide reductase in inhibition of mammalian cell growth by potent iron chelators. J. Biol. Chem. 268:1993;26200-26205.
143. Cooper C.E., Lynagh G.R., Hoyes K.P., Hider R.C., Cammack R., Porter J.B. The relationship of intracellular iron chelation to the inhibition and regeneration of human ribonucleotide reductase. J. Biol. Chem. 271:1996;20291-20299.
144. Gartel A.L., Tyner A.L. Transcriptional regulation of the p21(WAF1/CIP1) gene. Exp. Cell Res. 246:1999;280-289.
145. Biggs J.R., Kudlow J.E., Kraft A.S. The role of the transcription factor Sp1 in regulating the expression of the WAF1/CIP1 gene in U937 leukemic cells. J. Biol. Chem. 271:1996;901-906.
146. Fang L., Lee S.W., Aaronson S.A. Comparative analysis of p73 and p53 regulation and effector functions. J. Cell Biol. 147:1999;823-830.
147. Jost C.A., Marin M.C., Kaelin W.G. Jr. p73 is a simian [correction of human] p53-related protein that can induce apoptosis. Nature. 389:1997;191-194.
148. Graunke D.M., Fornace A.J. Jr., Pieper R.O. Presetting of chromatin structure and transcription factor binding poise the human GADD45 gene for rapid transcriptional up-regulation. Nucleic Acids Res. 27:1999;3881-3890.
149. Schwab M., Alitalo K., Klempnauer K.H., Varmus H.E., Bishop J.M., Gilbert F., Brodeur G., Goldstein M., Trent J. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumor. Nature. 305:1983;245-248.
150. Schwab M., Varmus H.E., Bishop J.M., Grzeschik K.H., Naylor S.L., Sakaguchi A.Y., Brodeur G., Trent J. Chromosomal localization in normal human cells and neuroblastomas of a gene related to c-myc. Nature. 308:1984;288-291.
151. Brodeur G.M., Seeger R.C., Schwab M., Varmus H.E., Bishop J.M. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science. 224:1984;1121-1124.
152. Hann H.W., Stahlhut M.W., Evans A.E. Serum ferritin as a prognostic indicator in neuroblastoma: biological effects of isoferritins. Prog. Clin. Biol. Res. 175:1985;331-345.
153. Modjtahedi N., Frebourg T., Fossar N., Lavialle C., Cremisi C., Brison O. Increased expression of cytokeratin and ferritin-H genes in tumorigenic clones of the SW 613-S human colon carcinoma cell line. Exp. Cell Res. 201:1992;74-82.
154. Fan L., Iyer J., Zhu S., Frick K.K., Wada R.K., Eskenazi A.E., Berg P.E., Ikegani N., Kennett R.H., Frantz C.N. Inhibition of N-myc expression and induction of apoptosis by iron chelation in human neuroblastoma cells. Cancer Res. 61:2001;1073-1079.
155. Kyriakou D., Eliopoulos A.G., Papadakis A., Alexandrakis M., Eliopoulos G.D. Decreased expression of c-myc oncoprotein by peripheral blood mononuclear cells in thalassaemia patients receiving desferrioxamine. Eur. J. Haematol. 60:1998;21-27.
156. Tomoyasui S., Fukuchi K., Yajima K., Watanabe K., Suzuki H., Kawakami K., Gomi K., Tsuruoka N. Suppression of HL-60 cell proliferation by deferoxamine: changes in c-myc expression. Anticancer Res. 13:1993;407-410.
157. Wu K.J., Polack A., Dalla-Favera R. Coordinated regulation of iron-controlling genes, H-ferritin and IRP2, by c-myc. Science. 283:1999;676-679.
158. Furukawa T., Adachi Y., Fujisawa J., Kambe T., Yamaguchi-Iwai Y., Sasaki R., Kuwahara J., Ikehara S., Tokunaga R., Taketani S. Involvement of PLAGL2 in activation of iron deficient- and hypoxia-induced gene expression in mouse cell lines. Oncogene. 20:2001;4718-4727.
159. Mizutani A., Furukawa T., Adachi Y., Ikehara S., Taketani S. A zinc-finger protein, PLAGL2, induces the expression of a proapoptotic protein Nip3, leading to cellular apoptosis. J. Biol. Chem. 277:2002;15851-15858.
160. Oltvai Z.N., Milliman C.L., Korsmeyer S.J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 74:1993;609-619.
161. Oda E., Ohki R., Murasawa H., Nemoto J., Shibue T., Yamashita T., Tokino T., Taniguchi T., Tanaka N. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science. 288:2000;1053-1058.
162. Nakano K., Vousden K.H. PUMA, a novel proapoptotic gene, is induced by p53. Mol. Cell. 7:2001;683-694.
163. Yu J., Zhang L., Hwang P.M., Kinzler K.W., Vogelstein B. PUMA induces the rapid apoptosis of colorectal cancer cells. Mol. Cell. 7:2001;673-682.
164. Oda K., Arakawa H., Tanaka T., Matsuda K., Tanikawa C., Mori T., Nishimori H., Tamai K., Tokino T., Nakamura Y., Taya Y. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell. 102:2000;849-862.
165. Okamura S., Arakawa H., Tanaka T., Nakanishi H., Ng C.C., Taya Y., Monden M., Nakamura Y. p53DINP1, a p53-inducible gene, regulates p53-dependent apoptosis. Mol. Cell. 8:2001;85-94.
166. Kastan M.B., Zhan Q., el-Deiry W.S., Carrier F., Jacks T., Walsh W.V., Plunkett B.S., Vogelstein B., Fornace A.J. Jr. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell. 71:1992;587-597.
167. de Rozieres S., Maya R., Oren M., Lozano G. The loss of mdm2 induces p53-mediated apoptosis. Oncogene. 19:2000;1691-1697.